血液幹細胞の画期的な進歩が骨髄移植を変えるかもしれない(Blood stem cell breakthrough could transform bone marrow transplants)

ad

2024-09-02 バーミンガム大学

ムルドック小児研究所(MCRI)とバーミンガム大学の研究チームが、ヒト胚に近い血液幹細胞の作成に成功しました。この画期的な発見は、白血病や骨髄不全疾患を持つ子供たちに対する個別化治療の可能性を広げるものです。研究では、特定の成長因子を使用して、移植可能な血液幹細胞を生成する方法が開発されました。これにより、適合するドナーが見つからない患者に対しても、個別に調整された血液幹細胞を提供できるようになり、治療の精度と安全性が向上することが期待されます。

<関連情報>

ヒト人工多能性幹細胞から分化した多系統造血細胞の長期生着 Long-term engrafting multilineage hematopoietic cells differentiated from human induced pluripotent stem cells

Elizabeth S. Ng,Gulcan Sarila,Jacky Y. Li,Hasindu S. Edirisinghe,Ritika Saxena,Shicheng Sun,Freya F. Bruveris,Tanya Labonne,Nerida Sleebs,Alexander Maytum,Raymond Y. Yow,Chantelle Inguanti,Ali Motazedian,Vincenzo Calvanese,Sandra Capellera-Garcia,Feiyang Ma,Hieu T. Nim,Mirana Ramialison,Constanze Bonifer,Hanna K. A. Mikkola,Edouard G. Stanley & Andrew G. Elefanty
Nature Biotechnology  Published:02 September 2024
DOI:https://doi.org/10.1038/s41587-024-02360-7

血液幹細胞の画期的な進歩が骨髄移植を変えるかもしれない(Blood stem cell breakthrough could transform bone marrow transplants)

Abstract

Hematopoietic stem cells (HSCs) derived from human induced pluripotent stem cells (iPS cells) have important biomedical applications. We identified differentiation conditions that generate HSCs defined by robust long-term multilineage engraftment in immune-deficient NOD,B6.Prkdcscid Il2rgtm1Wjl/SzJ KitW41/W41 mice. We guided differentiating iPS cells, as embryoid bodies in a defined culture medium supplemented with retinyl acetate, through HOXA-patterned mesoderm to hemogenic endothelium specified by bone morphogenetic protein 4 and vascular endothelial growth factor (VEGF). Removal of VEGF facilitated an efficient endothelial-to-hematopoietic transition, evidenced by release into the culture medium of CD34+ blood cells, which were cryopreserved. Intravenous transplantation of two million thawed CD34+ cells differentiated from four independent iPS cell lines produced multilineage bone marrow engraftment in 25–50% of immune-deficient recipient mice. These functionally defined, multipotent CD34+ hematopoietic cells, designated iPS cell-derived HSCs (iHSCs), produced levels of engraftment similar to those achieved following umbilical cord blood transplantation. Our study provides a step toward the goal of generating HSCs for clinical translation.

シグナル応答性エンハンサーのゲノムワイドなリレーが造血特異性を駆動する A genome-wide relay of signalling-responsive enhancers drives hematopoietic specification

B. Edginton-White,A. Maytum,S. G. Kellaway,D. K. Goode,P. Keane,I. Pagnuco,S. A. Assi,L. Ames,M. Clarke,P. N. Cockerill,B. Göttgens,J. B. Cazier & C. Bonifer
Nature Communications  Published:17 January 2023
DOI:https://doi.org/10.1038/s41467-023-35910-9

figure 1

Abstract

Developmental control of gene expression critically depends on distal cis-regulatory elements including enhancers which interact with promoters to activate gene expression. To date no global experiments have been conducted that identify their cell type and cell stage-specific activity within one developmental pathway and in a chromatin context. Here, we describe a high-throughput method that identifies thousands of differentially active cis-elements able to stimulate a minimal promoter at five stages of hematopoietic progenitor development from embryonic stem (ES) cells, which can be adapted to any ES cell derived cell type. We show that blood cell-specific gene expression is controlled by the concerted action of thousands of differentiation stage-specific sets of cis-elements which respond to cytokine signals terminating at signalling responsive transcription factors. Our work provides an important resource for studies of hematopoietic specification and highlights the mechanisms of how and where extrinsic signals program a cell type-specific chromatin landscape driving hematopoietic differentiation.

細胞遺伝子工学
ad
ad
Follow
ad
タイトルとURLをコピーしました